anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Stress is a subjective experience that varies across individuals depending on their sensitivity, resilience, and length of exposure to stressors. Stress may be categorised as acute (positive stress) or chronic (negative stress). Acute stress is advantageous for the human body, but chronic stress results in changes in cardiovascular, neuroendocrine, autonomic, and immunological functions, eventually causing different illnesses. The specific process relating stress to chronic stress associated diseases is still a topic of continuing debate. Inflammation has been recognised as a new and fascinating physiological mechanism that connects chronic stress and its associated illnesses. This article explored the relationships between chronic stress, inflammation, and chronic illnesses, including depression, cancer, and cardiovascular disease. This article also emphasises on various possible therapeutic targets for the management of chronic stress related illnesses by targeting inflammation, namely lipoxins and alpha7 nicotinic receptors. These therapeutic targets may be useful in developing new and safe therapies for the management of chronic stress related dysfunctions.
Phase III:Participants will receive placebo orally in combination with carboplatin and etoposide during the induction Cycles 1-4. Thereafter, participants will receive maintenance placebo until persistent radiographic PD, intolerable toxicity or withdrawal of consent, investigator's consideration, lost follow up, death ,study termination by the sponsor.whichever occurs first.
Surgical Infiltration of the study solution will be performed both prior to incision and at the end of surgery just prior to closure of incisions. At each time, the surgeon will inject 5 mL of 0.25% bupivacaine into each of the port site incisions.
MACH is a randomized trial of minocycline in intracerebral hemorrhage. 24 total subjects will be randomly assigned to minocycline or control (1:1). The first dose will be given intravenously. Subsequent doses will be given orally every 24 hours for a total of five doses. The study will test to see if the medication is safe in intracerebral hemorrhage. The pharmacokinetics of minocycline in intracerebral hemorrhage will be determined and the impact of minocycline on blood biomarkers.
TMARP standard of care intervention: 12 weeks of the Traditional Military Amputee Rehabilitation Program (TMARP). TMARP training starts 1 week after surgical closure of the residual limb. Physical Therapy performs Pre-Prosthetic Training for about 6 weeks, preparing for the prosthetic. After pre-prosthetic training, patients are fitted with their prosthetic leg and began post-prosthetic training with PT. The training focus is lower limb prosthetic proficient in ambulation.
The investigators want to include patients in Sweden that are eligible for surgical correction of their abdominal rectus diastasis. Patients will be recruited at the surgical clinic at four hospitals in Sweden. After being informed about the study and potential risks, all patient give written informed consent. Randomisation is performed upon inclusion.

All patients undergo surgery by plication of the linea alba. A blood sample is collected prior to the surgery. During the surgery the skin, connective tissue and rectus muscle are biopsied. On the first postoperative day, another blood sample is collected. Follow up is conducted three and twelve months after surgery.
Abstract The present disclosure is direct to methods and compositions for the treatment of multiple sclerosis using antipsychotic drugs. More specifically, the present disclosure is related to method and compositions for the treatment of multiple sclerosis using atypical antipsychotics such as risperidone, paliperidone or clozapine. Use of a drug with an affinity for both serotonergic 5-HT2 and dopaminergic D2 receptors in the preparation of a medicament for reducing at least one symptom of multiple sclerosis. WO 2012/012147 PCT/US2O1 1/042244 Fig. 2A 30mq' Mv day aft.r hnmun~zaticm: Fig. 2B cli OZ ): iw~ enOIISmVA '
<P>PROBLEM TO BE SOLVED: To prepare an easy-to-use skin patch drug which is soft, well-fitted to skin, and avoids the swelling of its base material sheet by preventing any medicine or excipient in its adhesive agent layer from moving to the base material sheet, and the base material sheet used for the drug it.  <P>SOLUTION: The base material sheet consists of a polyethylene terephthalate film of ≤10μm thick, and a polyolefin resin film of 50 to 200μm thick which is adhered to the polyethylene terephthalate film with an adhesive. The polyolefin resin film is composed of 50-100 wt.% of at least one kind selected from a low-density polyethylene resin and an olefin thermoplastic elastomer, 0-30 wt.% of a random polypropylene resin, and 0-20 wt.% of an ethylene-butylene random copolymer. The 10 % modulus of the base material sheet is at most 35 N/19mm in both length and width. The skin patch drug comprises the base material sheet and an adhesive layer containing a medicine laminated on the reverse side of the polyethylene terephthalate film used in the base material sheet.  <P>COPYRIGHT: (C)2004,JPO
Ivabradine is a recently introduced inhibitor of the If ion channel, which exhibits the capacity to reduce heart rate while preserving hemodynamic stability. At present, ivabradine finds its clinical indication in patients suffering from heart failure with reduced ejection fraction and maintaining a relative sinus rhythm refractory to beta-blockers. To optimize heart rate control, it is recommended to pursue an aggressive up-titration of ivabradine. This approach may ameliorate tachycardia-induced hypotension by incrementally enhancing cardiac output and allow further up-titration of agents aimed at ameliorating heart failure, such as beta-blockers. Both the modulation of heart rate itself and the up-titration of agents targeting heart failure lead to cardiac reverse remodeling, consequently culminating in a subsequent reduction in mortality and morbidity. A novel overlap theory that our team proposed recently has emerged in recent times. Under trans-mitral Doppler echocardiography, the E-wave and A-wave closely juxtapose one another without any overlapping at the optimal heart rate. Employing echocardiography-guided ivabradine for heart-rate modulation to minimize the overlap between the E-wave and A-wave appears to confer substantial benefits to patients with heart failure. This approach facilitates superior cardiac reverse remodeling and yields more favorable clinical outcomes when compared to those patients who do not receive echocardiography-guided care. The next pertinent issue revolves around the potential expansion of ivabradine's clinical indications to encompass a broader spectrum of diseases. It is imperative to acknowledge that ivabradine may not yield clinically significant benefits in patients afflicted by heart failure with preserved ejection fraction, acute heart failure, sepsis, or stable angina. An important fact yet to be explored is the clinical applicability of ivabradine in patients with atrial fibrillation, a concern that beckons future investigation. In this review, the concept of overlap theory it introduced, along with its application to expand the indication of ivabradine and the overlap theory-guided optimal ivabradine therapy.
Each session will last a maximum of 5 minutes, taking place for 3 days a week, over a period of 4 weeks. The intervention will be performed at the start of training (before warm-up).
Cohort 4 is limited to patients clinically diagnosed with Psoriasis. Patients in this cohort will receive the universal ClinROs and PROs (i.e. not disease specific) as well as additional PsO-specific measures throughout the length of the study.
The present invention relates to the field of stabilized biopolymer compositions, particularly to stabilized biopolymer compositions comprising a liquid mixture, in particular aqueous solution, of at least one biopolymer component and at least one stabilizing surfactant. More specifically, the present invention relates to stabilized biopolymer compositions comprising an ethylene oxide/butylene oxide block copolymer capable to confer to said biopolymer composition superior properties in comparison to the presently known formulations, particularly with regard to aggregation tendency, hemolytic activity and solubility. The invention further relates to said block copolymers, to methods for preparing said stabilized compositions and to the use of said block copolymers for stabilizing an aqueous composition of said biopolymer. The invention further relates said stabilized composition for use in medicine, in particular for diagnostic and/or therapeutic applications. The invention further relates to an essentially dry biopolymer composition, comprising said biopolymer and said block copolymers and to methods for preparing said essentially dry compositions. The invention further relates to said essentially dry biopolymer composition for use in medicine, in particular for diagnostic and/or therapeutic applications. Said compositions may be formulated as pharmaceutical compositions which may be delivered via suitable routes of administration such as via oral, rectal, transmucosal, topical, ophthalmic, otologic, or intestinal administration; parenteral delivery, including intramuscular, subcutaneous, intramedullary injections, as well as intrathecal, direct intraventricular, intravenous, intraperitoneal, intranasal, or intraocular injections, as the case may be.
PURPOSE:The titled composition obtained by incorporating at least one selected from basic amino acids, celluloses and mucopolysaccharides as an absorption promoter with kallidinogenase. CONSTITUTION:A composition for formulating easily absorbable kallidinogenase, obtained by incorporating 0.1-40.0mg, based on 1,000 units kallidinogenase, at least one selected from basic amino acids, e.g. L-arginine, L-lysine or L- histidine, celluloses, e.g. methyl cellulose or carboxymethyl cellulose, and mucopolysaccharides, e.g. mucin, chondroitin sulfate, hyaluronic acid or keratosulfate, as an absorption promoter with the kallidinogenase, and having good absorbability through the intestinal tracts. In producing the above- mentioned composition, albumin, e.g. bovine serum albumin or casein, etc., may be used as a stabilizer together, and the amount to be incorporated is preferably 0.1-200mg based on 1,000 units kallidinogenase as described above.
The invention discloses a traditional Chinese medicine composition for treating pharyngoconjunctival fever. The traditional Chinese medicine composition comprises grass-leaved sweetflag rhizome, radix curcumae, root of common fig, calamitas urinae hominis, bidens tripartite, Humulus scandens, tung tree fruit, puffball, common nipplewort, cucurbita moschata duch, Viola japonica, Hylocereus undwithus, Drymoglossum subcordatum, balsam pear and arnebia root. Root of common fig, calamitas urinae hominis, bidens tripartite, Humulus scandens, tung tree fruit, Viola japonica and Drymoglossum subcordatum have effects of clearing heat. Puffball, common nipplewort, cucurbita moschata duch and Hylocereus undwithus have effects of diminishing inflammation. Balsam pear and arnebia root have effects of resisting adenoviruses. Through combination of balsam pear and arnebia root, obvious synergism of resisting adenoviruses is obtained and is better than that of a single component. Radix curcumae has effects of clearing away the heart-fire and resolving depression. Grass-leaved sweetflag rhizome has effects of transforming dampness and promoting appetite. According to the basic principle of resisting bacteria, bringing down a fever and diminishing inflammation, through reasonable compatibility of the above drugs, the traditional Chinese medicine composition has effects of fast and thoroughly treating pharyngoconjunctival fever. The traditional Chinese medicine composition has a short treatment course of 1-3 days and has a cure rate of 100%.
OBJECTIVES: The purpose of this study was to examine factors associated with engagement in meaningful activity among residents with dementia in assisted living. We hypothesized that greater functional independence, less pain, and lower behavioral and psychological symptom severity would be associated with higher engagement in meaningful activity after controlling for residents' age, gender, comorbidities, and cognition. Understanding factors associated with engagement in meaningful activity can help to inform strategies for optimizing engagement among residents with dementia in assisted living.
METHOD: This descriptive study used baseline data from a randomized controlled trial, Meaningful Activity for Managing Behavioral Symptoms of Distress (MAC-4-BSD). Linear regression was used to examine factors associated with engagement in meaningful activity.
RESULTS: A total of 71 residents from 5 assisted living settings were included in the sample. Most participants were female (n = 52, 73%), White (n = 62, 87%), and mean age was 85 years old (SD = 8.2). Controlling for age, gender, comorbidities, and cognition, pain was significantly associated with engagement in meaningful activity (b= -2.09, p < 0.05). There were no associations found between function and behavioral symptoms with engagement in meaningful activity.
CONCLUSION: Findings from this study show that pain is a significant factor that is negatively associated with residents' engagement in meaningful activity. Ongoing research is needed to help improve pain management for residents with dementia in assisted living and support their engagement in meaningful activity.
PURPOSE:To provide an ultraviolet absorber containing cinnamic acid derivatives as active component, free from toxicity and stimulation to the skin as well as odor and color, effective in absorbing ultraviolet radiation, having excellent compatibility to oily base and organic solvent, etc., and useful as a component of cosmetics. CONSTITUTION:The objective ultraviolet absorber contains, as an active component, at least one compound selected from (A) cinnamic acid derivatives of formula I (R1 is 1-2C aliphatic group; R2 is H or 1-12C straight or branched aliphatic hydrocarbon group) compatible with an oily base and insoluble in water and (B) their salts of formula II (M is Na or K) having high solubility in water. The agent is useful especially for absorbing ultraviolet radiation of long wavelength range (about 400-320nm) and of medium wavelength range (about 320-280nm). It exhibits excellent effect in various kinds of cosmetic, e.g. high solubility in a cosmetic resistant to perspiration as well as in a water- soluble cosmetic. It has high stability to light and heat and is stable to cosmetic bases and cosmetic additives.
The invention provides application and blood-sugar lowering effective part of trapa acornis nakano shell as well as an extraction method of the blood-sugar lowering effective part, belonging to the technical field of traditional Chinese medicine. The new application of the trapa acornis nakano shell is to prepare a blood-sugar lowering medicine. The blood-sugar lowering effective part of the trapa acornis nakano shell is selected from one or any composite of petroleum ether part (TAPE), ethyl acetate part (TAEA) and n-butyl alcohol part (TABU) of the alcohol extract of trapa acornis nakano shell. The extraction method of the effective part comprises the following steps: grinding the dried trapa acornis nakano shell, carrying out digestion on the trapa acornis nakano shell powder with the aqueous solution of methyl alcohol or ethanol, and concentrating the immersion liquid to obtain extract; extracting the extract with petroleum ether, ethyl acetate or n-butyl alcohol for three times respectively; and volatilizing the dissolvent to obtain the TAPE, the TAEA or the TABU of the trapa acornis Nakai shell. Each effective part has good activity in inhibiting alpha-glucuroide. In vitro tests prove that TAEA and TABU have relatively good therapeutic effect on mice suffering from diabetic induced by mesoxyalyurea.
BACKGROUND: The radiological pattern of stroke patients with thrombophilia is unknown. Our aim is to compare the MRI radiological pattern of silent and acute lesions in cryptogenic stroke/TIA patients under 60 years of age with and without thrombophilia.
METHODS: Cryptogenic stroke/TIA patients under 60 years of age hospitalized at our Stroke Unit during four years were consecutively included. Thrombophilia screening was performed at 3 months after stroke and verified 12 weeks later. The follow-up was performed at 3, 12 and 24 months. Radiological pattern was assessed with the Fazekas and van Swieten scales.
RESULTS: During four years, 185 cryptogenic stroke/TIA patients under 60 years of age were included; mean age was 51 years, 61% were female, with a follow-up of 22±3.2 months. Thrombophilia was detected in 20% of patients. We detected a significant increase of previous vascular events (29.7% vs 7.5%, p=.01) as well as lower hypercholesterolemia (27% vs 62.5% p=.003) in the thrombophilia group, without significant differences in other vascular risk factors or vascular recurrence during follow-up. Regarding the acute lesion, we did not detect significant differences between groups. The radiological pattern of silent lesions showed that the thrombophilia group presented more large confluent lesions (39.1% vs 19.2%, p=.02) with greater sparing of the anterior territory (0% vs 30%, p=.01).
CONCLUSIONS: Our data suggest a characteristic radiological pattern of silent lesions in cryptogenic stroke/TIA patients with thrombophilia, with more confluent lesions and less involvement of the anterior territory.
The invention is a central server configured to control the receipt and analysis of patient medical data and patient information. The central server controls access to the patient medical data by an analysis workstation that is responsive to a medical specialist. The analysis workstation analyzes the patient medical data and prepares a medical report associated with the patient medical data. The central server comprises a first communication interface for receiving patient medical data and patient information from a remote computer and for transmitting the medical report associated with the patient medical data to the remote computer. A storage system stores the received patient medical data, patient information, and the associated medical report. A processor is configured to control access to and analysis of the patient medical data by the analysis workstation and the medical specialist and is configured to control access to the medical report. A second communication interface transmits the patient medical data to the analysis workstation and receives the associated medical report from the analysis workstation. The invention is also a method of controlling the acquisition and analysis of patient medical data over a network by a central server from a remote computer operably interconnected by the network with the central server.
Participants allocated to ORIF will undergo surgery within 72 hours from the diagnosis using a standard deltopectoral approach. An angular stable plate is used in all patients following manufacturer instructions. No drains will be used.
Monogenic disorders result from a single defective gene and are inherited according to Mendel's Laws (Mendelian disorders). Such gene defects arise from a mutation that can either be inherited or occur spontaneously; both may occur in the absence of a previous family history. Inherited mutations can be dominant or recessive, and autosomal or sex-linked. According to WHO, although individually rare, collectively monogenic disorders affect millions of people worldwide. Currently, over 10,000 human diseases are estimated to be monogenic. Until recently the identification of the genetic causes, especially of extremely rare phenotypes, has not been possible or cost effective due to the scientific challenges of identifying causative mutations through linkage analysis. The advent of cost effective next generation sequencing now facilitates the identification of all rare variants across the whole genome, in turn allowing mutation identification in small families and, if de novo, even in single cases.

The clinical application of single gene sequencing potentially provides tangible benefits to patients, informing diagnosis and prognosis, and may guide treatment choice. Next generation sequencing (NGS) panels sequence multiple genes in parallel and are now entering the clinical domain. NGS provides significant advantages over single gene sequencing for conditions which are genetically heterogeneous, such as the epilepsies. However, as more genes are included in an NGS panel, the possibility of incidental findings rises significantly, with associated challenges in result interpretation. Since many conditions are phenotypically as well as genetically heterogeneous, acquisition of detailed phenotypic information is essential for meaningful interpretation of NGS results.

Monogenic (Mendelian) disorders have historically provided the clearest means of elucidating human gene function. The linkage of a rare DNA variant to altered protein function or dose to discrete phenotype has important implications for fundamental biology, monogenic disease pathogenesis, complex traits, diagnostics and therapy. By representing the most readily interpretable component of human genetics in defining a clear, high-penetrance phenotype arising from alteration in function of a single gene, study of monogenic disorders can identify the genetic basis for novel or existing phenotypes and provide insights into non-redundant biological pathways that may inform therapeutic targeting for both the specific rare variant and common diseases. Accordingly the primary purpose of this programme is to identify novel monogenic phenotypes and discover underlying causal genetic variants by genetic sequencing in families across the UAE.
Animal studies have not been conducted to evaluate the carcinogenic potential of radium-223 dichloride. However, in repeat-dose toxicity studies in rats, osteosarcomas, a known effect of bone-seeking radionuclides, were observed at clinically relevant doses 7 to 12 months after the start of treatment. The presence of other neoplastic changes, including lymphoma and mammary gland carcinoma, was also reported in 12- to 15-month repeat-dose toxicity studies in rats. 

Genetic toxicology studies have not been conducted with radium-223 dichloride. However, the mechanism of action of radium-223 dichloride involves induction of double-strand DNA breaks, which is a known effect of radiation. 

Animal studies have not been conducted to evaluate the effects of radium-223 dichloride on male or female fertility or reproductive function. Xofigo may impair fertility and reproductive function in humans based on its mechanism of action.